Distribution patterns of human papillomavirus genotypes among women in Guangzhou, China.
Genotype distribution
Guangzhou
HPV infection
Journal
Infectious agents and cancer
ISSN: 1750-9378
Titre abrégé: Infect Agent Cancer
Pays: England
ID NLM: 101276559
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
03
04
2023
accepted:
28
09
2023
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Cervical cancer is associated with high-risk human papillomavirus (HR-HPV) infection in the world. We aimed to evaluate the status of HPV infection among women in Guangzhou, China. The study recruited 28,643 female patients from the Guangzhou Women and Children's Medical Center for HPV genotype testing between 2019 and 2021. 5668 patients were infected with HPV, resulting in an overall infection prevalence of 19.78%. The prevalence of HR-HPV was recorded at 13.94% (both single-infections and multi-infections), probably high-risk HPV/possibly carcinogenic (pHR-HPV) as 3.51%; and low-risk HPV (LR-HPV) as 3.56%. The most common HR-HPV genotype detected was HPV-52 with an infection rate of 4.99%, followed by HPV 58 (2.18%), 16 (2.12%), 51 (1.61%), 39 (1.19%), 56 (1.09%), 59 (0.85%), 18 (0.72%), 33 (0.61%), 31 (0.53%), 35 (0.20%), 45 (0.17%). Among LR-HPV genotypes, HPV-42 was the most common (1.08%), followed by 44 (0.77%), 81 (0.68%), 6 (0.48%), 43 (0.40%), 11 (0.23%) and 83 (0.07%). The prevalence of infection among different genotypes in pHR-HPV was: 68 (1.29%), 53 (1.21%), 66 (0.77%), 82 (0.25%), 73 (0.16%). Additionally, the prevalence of single genotype HPV infection exceeded that of multiple HPV infections except HPV-59. Our findings imply that HPV genotype infections in Guangzhou demonstrate a regional and age-related distribution. Therefore, these data can provide a substantial foundation for further epidemiologic analysis to control and prevent HPV infections in Guangzhou.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer is associated with high-risk human papillomavirus (HR-HPV) infection in the world. We aimed to evaluate the status of HPV infection among women in Guangzhou, China.
METHODS
METHODS
The study recruited 28,643 female patients from the Guangzhou Women and Children's Medical Center for HPV genotype testing between 2019 and 2021.
RESULTS
RESULTS
5668 patients were infected with HPV, resulting in an overall infection prevalence of 19.78%. The prevalence of HR-HPV was recorded at 13.94% (both single-infections and multi-infections), probably high-risk HPV/possibly carcinogenic (pHR-HPV) as 3.51%; and low-risk HPV (LR-HPV) as 3.56%. The most common HR-HPV genotype detected was HPV-52 with an infection rate of 4.99%, followed by HPV 58 (2.18%), 16 (2.12%), 51 (1.61%), 39 (1.19%), 56 (1.09%), 59 (0.85%), 18 (0.72%), 33 (0.61%), 31 (0.53%), 35 (0.20%), 45 (0.17%). Among LR-HPV genotypes, HPV-42 was the most common (1.08%), followed by 44 (0.77%), 81 (0.68%), 6 (0.48%), 43 (0.40%), 11 (0.23%) and 83 (0.07%). The prevalence of infection among different genotypes in pHR-HPV was: 68 (1.29%), 53 (1.21%), 66 (0.77%), 82 (0.25%), 73 (0.16%). Additionally, the prevalence of single genotype HPV infection exceeded that of multiple HPV infections except HPV-59.
CONCLUSION
CONCLUSIONS
Our findings imply that HPV genotype infections in Guangzhou demonstrate a regional and age-related distribution. Therefore, these data can provide a substantial foundation for further epidemiologic analysis to control and prevent HPV infections in Guangzhou.
Identifiants
pubmed: 37907979
doi: 10.1186/s13027-023-00541-8
pii: 10.1186/s13027-023-00541-8
pmc: PMC10617049
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
67Subventions
Organisme : Science and Technology Program of Guangzhou, China
ID : 202102020057
Organisme : Science and Technology Program of Guangzhou, China
ID : 202201011522
Organisme : Guangzhou Basic Research Program Jointly Funded by Municipal Schools and Colleges (Institutes)
ID : 202201020645
Organisme : Guangzhou Women and Children's Medical Center Clinical Doctoral Research Fund
ID : 2020BS023
Organisme : Pediatric Institute Foundation of Guangzhou Women and Children's Medical Center
ID : GWCMC2020-4-010
Informations de copyright
© 2023. The Author(s).
Références
Cancer Res. 2018 Mar 15;78(6):1418-1430
pubmed: 29339538
BMJ. 2022 Dec 15;379:e070115
pubmed: 36521855
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Arch Gynecol Obstet. 2020 Dec;302(6):1329-1337
pubmed: 32914222
J Med Virol. 2021 Aug;93(8):5103-5109
pubmed: 33847386
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1157-64
pubmed: 15894666
Arch Virol. 2020 Mar;165(3):731-736
pubmed: 31907615
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
PLoS One. 2011 May 03;6(5):e19244
pubmed: 21559276
J Med Virol. 2019 Jan;91(1):139-145
pubmed: 29981172
BMJ Open. 2021 Sep 2;11(9):e052016
pubmed: 34475188
Lancet Glob Health. 2023 Jan;11(1):e48-e58
pubmed: 36521952
Arch Gynecol Obstet. 2023 Jul;308(1):35-41
pubmed: 35904609
Lancet Infect Dis. 2007 Jul;7(7):453-9
pubmed: 17597569
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
Epidemiol Infect. 2021 May 18;149:e135
pubmed: 34001298
J Pathol. 2014 Dec;234(4):441-51
pubmed: 25043390
J Med Virol. 2015 Oct;87(10):1769-76
pubmed: 25963674
BMC Public Health. 2021 Jul 6;21(1):1329
pubmed: 34229639
J Infect Dis. 2005 Jun 1;191(11):1808-16
pubmed: 15871112
J Clin Lab Anal. 2018 Oct;32(8):e22581
pubmed: 29862560
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
Prev Med. 2021 Mar;144:106399
pubmed: 33388322